The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.

500+

Collective years of investing and operational experience

95

Portfolio companies

58

M&A and IPOs

26

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
IPO in 2017 (NASDAQ: ANAB)
IPO in 2018 (NASDAQ:APTX)
IPO in 2018; Acquired by Eli Lilly in 2018
IPO in 2018 (NASDAQ: GRTS)
IPO in 2014; Acquired by Roche in 2018
NASDAQ: IOVA
IPO in 2018 (NASDAQ: ITRM)

Life Sciences News

Passage Bio

Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases

Recida Therapeutics

Frazier Healthcare Partners Launches Recida Therapeutics to Develop Novel Therapeutics for Serious Antibiotic-Resistant Infections

Amunix Pharmaceuticals

Amunix Announces Licensing Agreement with Merck for ProTIA Immune Activator Platform

Mirum Pharmaceuticals

Mirum Pharmaceuticals Secures $120 Million in Series A Financing to Develop Phase 3-Ready Maralixibat for Rare Liver Diseases

View All News